Citations

Clear

4847 citation(s) found for "Yu, Eric".

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles
Begna, Kebede H. , Altman, Jessica K. , Goldberg, Stuart L. , Rubenstein, S. Eric, Arellano, Martha , Baer, Maria R. , Gautier, Marc, Berman, Ellin , Seiter, Karen , Solomon, Scott R. , Schiller, Gary J. , Luger, Selina M. , Thomas, Xavier , Rizzieri, David A. , Quick, Donald P., Agura, Edward, Subramanian, Janakiraman , Maness, Lori J., Robert, Daniel-Eric, Hicheri, Yosr , Kadia, Tapan M. , Chiao, Judy H. , Kantarjian, Hagop M. , Goldberg, Stuart L. , Sekeres, Mikkael A. , Strickland, Stephen Anthony , Claxton, David F. , Butrym, Aleksandra , Gaïdano, Gianluca , Montesinos, Pau , Venugopal, Parameswaran , Ravandi, Farhad , Buyse, Marc

Mayo Clinic

Blood | April 6, 2021 | Volume: 130 | Issue: Suppl_1 | Pages: 891-891

10.1182/blood.v130.suppl_1.891.891 Get It

Abstract Background: Sapacitabine is a novel oral nucleoside analogue with a unique ability to induce single-strand DNA breaks after incorporation into DNA, leading to production of double-strand DNA breaks and/or G2 cell cycle arrest. In AML cell lines, the active metabolite of sapacitabine, CNDAC, is synergistic with hypomethylating agents (HMAs) particularly when treated with HMAs first. In a pilot study, there were 6 CRs and 2 PRs in 25 patients treated with sapacitabine in alternating cycles with decitabine. This global randomized phase 3 study evaluated the survival benefit of this treatment strategy vs. decitabine monotherapy. Methods: Decitabine 20 mg/m2 was administered intravenously daily x 5 days of a 4-week cycle (for the control arm and odd cycles of the study arm) alternating with sapacitabine 300 mg p.o. b.i.d. x 3 days/week x 2 weeks of a 4-week cycle (even cycles of the study arm). The safety of these doses was further evaluated in the lead-in phase of the phase 3 study to confirm the findings from the pilot study. Eligible patients were ≥70 years with untreated AML and unsuitable for or unwilling to receive standard induction chemotherapy. Patients who had received HMAs for prior MDS or MPD were excluded. Results: For 482 patients randomized to receive decitabine/sapacitabine (n=241) vs. decitabine only (n=241), randomization was stratified by the presence of antecedent MDS or MPN, peripheral white blood cell count (WBC <10,000 vs. ≥10,000) and bone marrow blast percentage (≥50% vs. < 50%). Median age was 77 years (range 70-90), and 317 patients had de novo AML (66%), 165 secondary AML (34%). WBC was ≥10,000 in 161 patients (33%) and >40,000 in 59 patients (12%); 194 patients (40%) had unfavorable cytogenetic risk by SWOG criteria. Disease characteristics were well balanced in both arms. In total, 13.7% of patients achieved CR, more on the study arm vs. control (16.6% vs. 10.8%). A total of 37.3% treated patients received ≥5 cycles of treatment, similar on both arms, as were 30- and 60-day death rates. Median overall survival was 5.9 months on the study arm vs. 5.7 months on control arm, which did not reach a statistically significant difference. In the subgroup of patients with <10,000 WBC (n=321), median overall survival was higher on the study arm vs. control arm (8.0 months vs. 5.8 months), as was CR rate (21.5% vs. 8.6%). Grade 3 or higher adverse events (regardless of causality) that occurred in >10% patients were thrombocytopenia, anemia, neutropenia, pneumonia, febrile neutropenia, sepsis, and disease progression. Conclusion: The regimen of sapacitabine administered in alternating cycles with decitabine was active and well tolerated but it did not significantly improve overall survival as compared to decitabine monotherapy. Further analyses are being conducted to characterize the subgroups of patients who appeared to have benefited from this treatment regimen and the potential cost savings associated with the use of an oral drug. Disclosures Kantarjian: Amgen: Research Funding; Pfizer: Research Funding; Delta-Fly Pharma: Research Funding; ARIAD: Research Funding; Bristol-Meyers Squibb: Research Funding; Novartis: Research Funding. Goldberg: Novartis: Honoraria, Research Funding, Speakers Bureau; Bristol Myers Squibb: Research Funding, Speakers Bureau; Celgene: Speakers Bureau; COTA: Employment, Equity Ownership; Pfizer: Honoraria; Ariad: Speakers Bureau; Jazz: Speakers Bureau. Sekeres: Celgene: Membership on an entity's Board of Directors or advisory committees. Strickland: Boehringer Ingelheim: Consultancy; Daiichi Sankyo: Consultancy; CTI BioPharma: Consultancy; Tolero Pharmaceuticals: Consultancy; Sunesis Pharamaceuticals: Consultancy, Research Funding; Baxalta: Consultancy; Alexion Pharmaceuticals: Consultancy; Astellas Pharma: Honoraria. Rubenstein: Alexion Pharmaceuticals: Speakers Bureau. Arellano: Cephalon Oncology: Research Funding. Schiller: bluebird bio: Research Funding; mateon therapeutics: Research Funding. Gaidano: Roche: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. Montesinos: Celgene Corporation: Honoraria, Research Funding. Rizzieri: Shire: Research Funding; Erytech: Research Funding. Subramanian: Boehringer-Ingelheim, Lilly, BMS, Astra-Zeneca, Pfizer, Biocept: Consultancy, Speakers Bureau. Buyse: IDDI: Employment, Equity Ownership. Chiao: Cyclacel LTD: Employment, Equity Ownership.
Crossing the Carotid Siphon: Techniques to Facilitate Distal Access in Tortuous Anatomy: 2-Dimensional Operative Video
Hadley, Caroline , Burkhardt, Jan‐Karl , Johnson, Jeremiah N., Kan, Peter , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levitt, Michael R. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Ogilvy, Christopher S. , Levitt, Michael R , Burkhardt, Jan-Karl , Schirmer, Clemens M , Ogilvy, Christopher S , Burkhardt, Jan‐Karl , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | April 6, 2021 | Volume: 21 | Issue: 1 | Pages: E41-E42

10.1093/ons/opab084 | PMID 33822191 Get It

Abstract As capabilities for endovascular treatment of intracranial vascular pathologies continue to expand, the need for access to the distal internal carotid artery with rigid support catheter systems continues to increase. One of the dominant factors limiting this access is patient anatomy, specifically vessel tortuosity. Increased tortuosity of the carotid siphon is a frequently encountered anatomic variant and may complicate endovascular procedures in adults and children. 1,2 Failed attempts to navigate the carotid siphon with a distal access catheter carry a risk of vessel injury and treatment failure. For this reason, techniques that aid in supporting safe advancement of a distal access catheter across a tortuous carotid siphon are essential. 3,4 In this video, we demonstrate 2 ways in which this may be accomplished. The first technique uses a larger diameter microcatheter, such as the AXS Offset catheter (Stryker, Kalamazoo, Michigan), to increase support for the distal access catheter, while the second uses a buddy wire technique to accomplish this increased support. Both of these techniques can help increase the safety of navigating a tortuous carotid siphon and increase the likelihood of successful treatment. The procedures shown were performed with the informed consent of the patients.
Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
Privitera, Michael , Bhathal, Hari, Wong, Matthew H. , Cross, J. Helen , Wirrell, Elaine , Marsh, Eric D. , Mazurkiewicz‐Bełdzińska, Maria , Villanueva, Vicente , Checketts, Daniel, Knappertz, Volker, VanLandingham, Kevan, Wirrell, Elaine C , Cross, Helen J , Mazurkiewicz-Bełdzińska, Maria , Wong, Matthew

Mayo Clinic

Epilepsia | April 2, 2021 | Volume: 62 | Issue: 5 | Pages: 1130-1140

10.1111/epi.16878 | PMID 33797076 Get It

AbstractObjectiveTo estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses of data from two randomized, placebo‐controlled, Phase 3 trials, GWPCARE3 (NCT02224560) and GWPCARE4 (NCT02224690), of patients with Lennox–Gastaut syndrome.MethodsPatients received plant‐derived pharmaceutical formulation of highly purified CBD (Epidiolex, 100 mg/ml oral solution) at 10 mg/kg/day (CBD10; GWPCARE3) or 20 mg/kg/day (CBD20; both trials) or placebo for 14 weeks. Treatment started at 2.5 mg/kg/day for all groups and reached 10 mg/kg/day on Day 7 and 20 mg/kg/day (CBD20 and matching placebo only) on Day 11. Percentage change from baseline in drop seizure frequency was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated.ResultsOverall, 235 patients received CBD (CBD10 [GWPCARE3 only],n = 67; CBD20 [pooled GWPCARE3&4],n = 168) and 161 received placebo. Mean (range) age was 15.3 years (2.6–48.0). Patients had previously discontinued a median (range) of six (0–28) antiepileptic drugs (AEDs) and were currently taking a median of three (0–5) AEDs. Differences in drop seizure reduction between placebo and CBD emerged during the titration period and became nominally significant by Day 6 (p = .008) for pooled CBD treatment groups. Separation between placebo and CBD in ≥50% responder rate emerged by Day 6. Onset of the first reported AE occurred during the titration period in 45% of patients (CBD10, 46%; CBD20, 52%; placebo, 38%). In patients with AEs, resolution occurred within 4 weeks of onset in 53% of placebo and 39% of CBD patients and by end of study in 63% of placebo and 61% of CBD patients.SignificanceTreatment effect (efficacy and AEs) of CBD may occur within 1 week of starting treatment. Although AEs lasted longer for CBD than placebo, most resolved within the 14‐week period.
Association of Virtual Surgical Planning With External Incisions in Complex Maxillectomy Reconstruction
Moore, Eric J. , Price, Daniel L., Abel, Kathryn M. Van , Janus, J.R., Moore, Ethan , Martin, Eli, Morris, Johnathan M., Alexander, Amy E. , Janus, Jeffery R, Moore, Ethan T, Van Abel, Kathryn M , Price, Daniel L. , Martin, Eliot J., Morris, Johnathan M.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 1, 2021 | Volume: 147 | Issue: 6 | Pages: 526

10.1001/jamaoto.2021.0251 | PMID 33792635 Get It

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
Fuchs, Charles S. , Shitara, Kohei , Muro, Kei , Vita, Ferdinando De , Landers, Gregory, Yen, Chia‐Jui , Chau, Ian , Elme, Anneli , Lee, Jeeyun , Özgüroğlu, Mustafa , Catenacci, Daniel V.T. , Yoon, Harry H. , Chen, Erluo, Adelberg, David E., Shih, Chie‐Schin , Shah, Sukrut, Bhagia, Pooja , Yen, Chia-Jui , Özgüroğlu, Mustafa , Chao, Joseph , Tabernero, Josep , Cutsem, Eric Van , Bang, Yung‐Jue , Wainberg, Zev A.

Mayo Clinic

JAMA Oncology | April 1, 2021 | Volume: 7 | Issue: 6 | Pages: 895

10.1001/jamaoncol.2021.0275 | PMID 33792646 Get It

Short and long‐term outcomes of three‐dimensional printed surgical guides and virtual surgical planning versus conventional methods for fibula free flap reconstruction of the mandible: Decreased nonunion a
May, Matthew M. , Howe, Benjamin M., O’Byrne, Thomas J., Alexander, Amy E. , Morris, Jonathon M., Moore, Eric J. , Kasperbauer, Jan L. , Janus, Jeffrey R. , Abel, Kathryn M. Van , Dickens, Hunter J., Van Abel, Kathryn M , Howe, Benjamin M. , Price, Daniel L.

Mayo Clinic

Head & Neck | March 31, 2021 | Volume: 43 | Issue: 8 | Pages: 2342-2352

10.1002/hed.26688 | PMID 33786910 Get It

Abstract Background To determine whether virtual surgical planning and three‐dimensional printed cutting guides (3D/VSP) improved radiographic bone union compared to conventional methods (CM) in fibula free flap (FFF) reconstruction of the mandibles. Methods Retrospective study from the years 2000–2018 at a tertiary hospital. Osseous union was evaluated by a radiologist blinded to each patient's treatment. Results Two hundred sixty patients who underwent FFF tissue transfer, 28 with VSP and 3D cutting guides. Bony union was not achieved in 46 (20%) patients who underwent CM compared to 1 (4%) of patients with VSP and guides ( p = 0.036). FFF complication was significantly higher in CM with 87 patients (38%) compared to three patients (11%) in 3D/VSP ( p = 0.005). Median time to bony union for patients who underwent CM was 1.4 years compared to 0.8 years in 3D/VSP. Conclusions 3D/VSP reduced the rate of radiographic nonunion and flap‐related complications in FFF reconstruction for mandibular defects.
Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman Primates
Chowdhury, Uttio Roy, Kudgus, Rachel A. , Holman, Bradley H., Rinkoski, Tommy A. , Hann, Cheryl R., Bahler, Cindy K., McCloud, Eric, Appt, Susan E. , Fautsch, Michael P. , Roy Chowdhury, Uttio, Reid, Joel M. , McCloud, Eric, Dosa, Peter I.

Mayo Clinic

Journal of Ocular Pharmacology and Therapeutics | March 30, 2021 | Volume: 37 | Issue: 5 | Pages: 251-260

10.1089/jop.2020.0137 | PMID 33784195 Get It

Purpose: To evaluate pharmacokinetic parameters and ocular hypotensive effects of cromakalim prodrug 1 (CKLP1) in normotensive large animal models. Methods: Optimal CKLP1 concentration was determined by dose response and utilized in short- (5–8 days) and long-term (60 days) evaluation in hound dogs ( n = 5) and African Green Monkeys ( n = 5). Blood pressure was recorded 3–5 times per week with a tail cuff. Concentrations of CKLP1 and the parent compound levcromakalim were assessed in hound dog plasma and select tissues by LC-MS/MS after bilateral ocular treatment with CKLP1 for 8 days. Pharmacokinetic parameters were calculated from days 1, 4, and 8 data. After necropsy, histology was assessed in 43 tissue samples from each animal. Results: In hound dogs and African Green monkeys, 10 mM CKLP1 (optimal concentration) significantly lowered intraocular pressure (IOP) by 18.9% ± 1.1% and 16.7% ± 6.7%, respectively, compared with control eyes ( P < 0.05). During treatment, no significant change in systolic or diastolic blood pressure was observed in either species ( P > 0.1). Average values for half-life of CKLP1 was 295.3 ± 140.4 min, C max, 10.5 ± 1.6 ng/mL, and area under the concentration vs. time curve (AUC last ) 5261.4 ± 918.9 ng·min/mL. For levcromakalim, average values of half-life were 96.2 ± 27 min, C max 1.2 ± 0.2 ng/mL, and AUC last 281.2 ± 110.8 ng·min/mL. No significant pathology was identified. Conclusions: CKLP1 lowered IOP in hound dogs and African green monkeys with no effect on systemic blood pressure. Ocular topical treatment of CKLP1 showed excellent tolerability even after extended treatment periods.
Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE ɛ3/ɛ4 Carriers
Edlund, Anna , Lee, Wendy , Protas, Hillary , Su, Yi , Reiman, Eric M. , Caselli, Richard J. , Nielsen, Henrietta M. , Reiman, Eric, Edlund, Anna K., Chen, Kewei

Mayo Clinic

Journal of Alzheimer's Disease | March 30, 2021 | Volume: 81 | Issue: 1 | Pages: 339-354

10.3233/jad-210065 | PMID 33814450 Get It

Background: Altered cerebral glucose metabolism, especially prominent in APOE ɛ4 carriers, occurs years prior to symptoms in Alzheimer’s disease (AD). We recently found an association between a higher ratio of plasma apolipoprotein E4 (apoE4) over apoE3, and cerebral glucose hypometabolism in cognitively healthy APOE ɛ3/ɛ4 subjects. Plasma apoE does not cross the blood-brain barrier, hence we speculate that apoE is linked to peripheral glucose metabolism which is known to affect glucose metabolism in the brain. Objective: Explore potential associations between levels of plasma insulin and glucose with previously acquired plasma apoE, cerebral metabolic rate of glucose (CMRgl), gray matter volume, and neuropsychological test scores. Methods: Plasma insulin and glucose levels were determined by ELISA and a glucose oxidase assay whereas apoE levels were earlier quantified by mass-spectrometry in 128 cognitively healthy APOE ɛ3/ɛ4 subjects. Twenty-five study subjects had previously undergone FDG-PET and structural MRI. Results: Lower plasma apoE3 associated with higher plasma glucose but not insulin in male subjects and subjects with a body mass index above 25. Negative correlations were found between plasma glucose and CMRgl in the left prefrontal and bilateral occipital regions. These associations may have functional implications since glucose levels in turn were negatively associated with neuropsychological test scores. Conclusion: Plasma apoE3 but not apoE4 may be involved in insulin-independent processes governing plasma glucose levels. Higher plasma glucose, which negatively affects brain glucose metabolism, was associated with lower plasma apoE levels in APOE ɛ3/ɛ4 subjects. High plasma glucose and low apoE levels may be a hazardous combination leading to an increased risk of AD.
Relationship of Body Mass Index With Fuchs Endothelial Corneal Dystrophy Severity and TCF4 CTG18.1 Trinucleotide Repeat Expansion
Kinariwala, Bhumi B., Xu, Timothy T., Baratz, Keith H., Aleff, Ross A., Patel, Sanjay V., Maguire, Leo J., Fautsch, Michael P., Wieben, Eric D., Millen, Amy E., Patel, Sangita P., Kinariwala, Bhumi B., Xu, Timothy T., Baratz, Keith H., Aleff, Ross A., Patel, Sanjay V., Maguire, Leo J., Fautsch, Michael P., Wieben, Eric D., Millen, Amy E., Patel, Sangita P.

Mayo Clinic

Cornea | March 30, 2021 | Volume: 40 | Issue: 12 | Pages: 1567-1570

10.1097/ico.0000000000002689 | PMID 33782268 Get It

Purpose: To investigate the association of body mass index (BMI) with Fuchs endothelial corneal dystrophy (FECD) severity and TCF4 CTG18.1 expansion. Methods: A total of 343 patients with FECD were enrolled from the Mayo Clinic. FECD severity was graded by slit-lamp biomicroscopy. BMI values were obtained from the electronic medical records. DNA extracted from leukocytes was analyzed for CTG18.1 expansion length, with ≥40 repeats considered expanded. Wilcoxon signed-rank tests were used to compare FECD grade and CTG18.1 expansion length in patients by BMI (<25, ≥25 to <30, and ≥30 kg/m2). FECD grade was regressed on age, sex, BMI, and CTG18.1 expansion and, separately, BMI on CTG18.1 expansion. Models were investigated for effect modification by age and sex with an interaction term of P < 0.05 considered statistically significant. Results: When examining the association between BMI and FECD, there was a significant interaction between BMI and sex (P for interaction = 0.004). When controlling for age and CTG18.1 expansion, a positive association was observed between BMI and FECD grade in women, but not in men. In addition, BMI was not associated with CTG18.1 expansion when controlling for age and sex. Conclusions: BMI was positively associated with FECD severity among women but not men. There was no significant association between BMI and CTG18.1 expansion. These findings suggest that increased BMI is potentially a modifiable risk factor for FECD disease progression among women.
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis
Fasching, Peter A. , Yadav, Siddhartha , Wunderle, Marius , Häberle, Lothar , Hart, Steven N. , Rübner, Matthias, Polley, Eric C. , Lee, Kun Y. , Hadji, Peyman , Hübner, H., Tesch, Hans , Ettl, Johannes , Overkamp, Friedrich , Ekici, Arif B. , Volz, Bernhard , Uhrig, Sabrina , Lüftner, Diana , Müller, Volkmar , Belleville, Erik, Kolberg, Hans‐Christian , Beckmann, Matthias W. , Hartmann, Arndt , Janni, Wolfgang , Taran, Florin‐Andrei , Fehm, Tanja , Wallwiener, D. , Schneeweiß, Andreas , Chen, Chen , Hu, Chunling , Wunderle, Marius , Hart, Steven N , Polley, Eric C , Lee, Kun Y , Gnanaolivu, Rohan D., Hübner, Hanna , Lux, Michael P , Ekici, Arif B , Müller, Volkmar , Untch, Michael , Kolberg, Hans-Christian , Reis, André , Schneeweiss, Andreas , Hartkopf, Andreas D , Couch, Fergus J. , Chen, C , Yadav, Siddhartha , Fehm, Tanja , Hu, Chunling , Gnanaolivu, Rohan , Lux, Michael P. , Wallwiener, Markus , Untch, Michael , Reis, André , Wimberger, Pauline , Brucker, Sara Yvonne , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2021 | Volume: 39 | Issue: 15 | Pages: 1619-1630

10.1200/jco.20.01200 | PMID 33780288 Get It

PURPOSE Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome. PATIENTS AND METHODS Germline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes. The frequencies of mutations in known BC predisposition genes were compared with results from a prospective registry of patients with nonmetastatic BC sequenced using the same QIAseq method and with public reference controls. Associations between mutation status and tumor characteristics, progression-free survival, and overall survival were assessed. RESULTS Germline mutations in 12 established BC predisposition genes (including BRCA1 and BRCA2) were detected in 271 (10.4%) patients. A mutation in BRCA1 or BRCA2 was seen in 129 patients (5.0%). BRCA1 mutation carriers had a higher proportion of brain metastasis (27.1%) compared with nonmutation carriers (12.8%). Mutations were significantly enriched in PRAEGNANT patients with mBC compared with patients with nonmetastatic BC (10.4% v 6.6%, P < .01). Mutations did not significantly modify progression-free survival or overall survival for patients with mBC. CONCLUSION Multigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in BRCA1/2 and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.